In my cart

You have no items in your shopping cart.

GYKI 53655 hydrochloride

(HB0312)
Data

Product overview

  • Name
    GYKI 53655 hydrochloride
  • Short description
    Non-competitive AMPA receptor antagonist
  • Biological description

    Non-competitive AMPA and kainate receptor antagonist. Analog of GYKI 52466.

    GYKI 53655 acts via an allosteric site at the AMPAR and inhibits channel gating downstream of glutamate binding.


    The compound inhibits AMPA - mediated response in cells expressing human GluR1(GluA1) and GluR4(GluA4) (IC50 values are 6 µM and 5 µM for GluA1 and GluA4 subunits respectively).

    At higher concentrations, GYKI 53655 also blocks kainate GluK3 homomeric receptors (IC50 = 63 μM) and GluK2b(R)/GluK3 heteroreceptors (IC50 = 32 μM).


    Active in vivo. Shows anticonvulsive and neuroprotective effects.

  • Alternative names
    LY300168
  • Biological action
    Antagonist
  • Purity
    >98%
  • Citations

Properties

  • Chemical name
    1-(4-Aminophenyl)-3-methylcarbamyl- 4-methyl-3,4-dihydro-7,8-methylenedioxy-5H-2,3-benzodiazepine hydrochloride
  • Molecular Weight
    388.85
  • Chemical structure
    GYKI 53655  [143692-18-6]
  • Molecular Formula
    C19H20N4O3.HCl
  • CAS Number
    143692-18-6
  • PubChem identifier
    126757
  • SMILES
    Cl.Nc1ccc(cc1)C3=NN(C(C)Cc2cc4OCOc4cc23)C(=O)NC
  • Source
    Synthetic
  • InChi
    InChI=1S/C19H20N4O3.ClH/c1-11-7-13-8-16-17(26-10-25-16)9-15(13)18(22-23(11)19(24)21-2)12-3-5-14(20)6-4-12;/h3-6,8-9,11H,7,10,20H2,1-2H3,(H,21,24);1H
  • InChiKey
    ASLCSBBDVWPSQT-UHFFFAOYSA-N
  • MDL number
    MFCD01941362
  • Appearance
    Orange solid

Storing and Using Your Product

  • Storage instructions
    Room temperature (desiccate)
  • Solubility overview
    Soluble in water (100mM, gentle warming) and in DMSO (100 mM)
  • Important
    This product is for RESEARCH USE ONLY and is not intended for therapeutic or diagnostic use. Not for human or veterinary use.

References for GYKI 53655 hydrochloride

  • Negative allosteric modulation of wild-type and mutant AMPA receptors by GYKI 53655.

    Partin KM et al (1996) Mol Pharmacol 49(1) : 142-8.
    PubMedID: 8569699
  • Activity of 2,3-benzodiazepines at native rat and recombinant human glutamate receptors in vitro: stereospecificity and selectivity profiles.

    Bleakman D et al (1996) Neuropharmacology 35(12) : 1689-702.
    PubMedID: 9076748
  • Blocking the trigeminal EPSP in rat abducens motoneurons in vivo with the AMPA antagonists NBQX and GYKI 53655.

    Ruiz A et al (2000) Brain Res Bull 52(2) : 99-107.
    PubMedID: 10808079
  • Comparison of anticonvulsive and acute neuroprotective activity of three 2,3-benzodiazepine compounds, GYKI 52466, GYKI 53405, and GYKI 53655.

    Szabados T et al (2001) Brain Res Bull 55(3) : 387-91.
    PubMedID: 11489346
Support & Resources